Adaptive Biotechnologies (ADPT) reported a quarterly loss of $0.10 per share, which was better than the Zacks Consensus Estimate of a loss of $0.13. This marks an earnings surprise of 23.08%, following a pattern where the company has exceeded consensus EPS estimates in all four of the last quarters. The firm also reported revenues of $71.55 million, surpassing expectations by nearly 8%. Year-to-date, ADPT shares have increased by 38.7%, significantly outperforming the S&P 500’s 8.5% gain. Investors are keenly watching future earnings outlooks, as a favorable trend in estimate revisions could influence stock performance further.
Disclaimer: This summary is written by AI, which can make mistakes. Please follow up on any news information from additional sources.
Link to original article source: https://finance.yahoo.com/healthcare/articles/adaptive-biotechnologies-adpt-reports-q2-222503985.html
